Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 79 Intrinsic Value: Projected FCF is $0.49 as of Sep. 21, 2026. GuruFocus rates MNIVF with a GF Score™ of 79/100 and a GF Value™ of $0.61. The stock has 10 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 78.3% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), Monash IVF Group's Intrinsic Value: Projected FCF is $0.49. The stock price of Monash IVF Group is $0.40. Therefore, Monash IVF Group's Price-to-Intrinsic-Value-Projected-FCF of today is 0.8.
The historical rank and industry rank for Monash IVF Group's Intrinsic Value: Projected FCF or its related term are showing as below:
MNIVF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.3 Med: 0.75 Max: 1.19
Current: 0.82
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Monash IVF Group was 1.19. The lowest was 0.30. And the median was 0.75.
MNIVF's Price-to-Projected-FCF is ranked better than 78.3% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.46
vs MNIVF: 0.82
Monash IVF Group (OTCPK:MNIVF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Monash IVF Group's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.40
/
0.6326668982746
=
0.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group Intrinsic Value: Projected FCF Related Terms
Monash IVF Group Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group Intrinsic Value: Projected FCF Chart
MNIVF vs TMO, DHR, NTRA: Intrinsic Value: Projected FCF Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group Price-to-Projected-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's Price-to-Projected-FCF falls into.
Monash IVF Group Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.49 mean?
Monash IVF Group (MNIVF) has a Intrinsic Value: Projected FCF of $0.49 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Monash IVF Group and its competitors. According to the industry distribution chart, Monash IVF Group ranks #23 out of 106 companies in the Medical Diagnostics & Research industry, placing it in the top 21.7%.
Is Monash IVF Group's Intrinsic Value: Projected FCF too high?
Monash IVF Group's current Intrinsic Value: Projected FCF is $0.49. The Medical Diagnostics & Research industry median Intrinsic Value: Projected FCF is 1.46. Monash IVF Group's value of $0.49 is 66.4% below this industry median. Based on the distribution chart, Monash IVF Group ranks #23 out of 106 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Monash IVF Group has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's Intrinsic Value: Projected FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #23 out of 106 companies for Intrinsic Value: Projected FCF. This places Monash IVF Group in the top 22% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.46. Monash IVF Group's value of $0.49 is 66.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Diagnostics & Research company?
The median Intrinsic Value: Projected FCF among Medical Diagnostics & Research companies is 1.46, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current Intrinsic Value: Projected FCF of $0.49 is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median Intrinsic Value: Projected FCF is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current Intrinsic Value: Projected FCF is $0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current Intrinsic Value: Projected FCF of $0.49. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.49 and 66.4% below the Medical Diagnostics & Research industry median of 1.46. Monash IVF Group's overall GF Score™ is 79/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current Intrinsic Value: Projected FCF is $0.49 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
Key valuation signals for MNIVF:
Intrinsic Value: Projected FCF: $0.49
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
Industry Position: 66.4% below the Medical Diagnostics & Research median (#23 of 106)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
79GF Score
Get the complete analysis for MNIVF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
